• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report
We report the case of a 70-year-old Asian woman (never smoker) who was diagnosed with lung adenocarcinoma in May 2014. Testing at diagnosis was negative for programmed death ligand 1 orEGFR,ALK, andROS1 alterations. She was started on carboplatin-pemetrexed-bevacizumab and maintenance bevacizumab but progressed in September 2015. Subsequently, she progressed on second-line nivolumab and third-line docetaxel. In March 2016, pleural fluid obtained at diagnosis tested positive for theBRAF V600E mutation and she received dabrafenib plus trametinib. She experienced rapid tumor shrinkage and symptom improvement and became able t...
Source: Clinical Drug Investigation - June 26, 2019 Category: Drugs & Pharmacology Source Type: research

Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
Abstract PURPOSE: We performed a systematic review of patient-centered outcomes after the concomitant use of proton pump inhibitors (PPIs) and other drugs. METHODS: We searched 4 databases in July 2016 to find studies that reported mortality and morbidity after the concomitant use of PPIs and other drugs. We conducted direct meta-analyses using a random-effects model and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation working group approach. FINDINGS: We included data from 17 systematic reviews and meta-analyses, 16 randomized controlled t...
Source: Clinical Therapeutics - February 8, 2017 Category: Drugs & Pharmacology Authors: Shamliyan TA, Middleton M, Borst C Tags: Clin Ther Source Type: research

Intraoperative stroke in the mandibular osteoradionecrosis: A case report
Publication date: January 2015 Source:Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, Volume 27, Issue 1 Author(s): Ryo Sasaki , Chie Kagawa , Toshihiro Okamoto , Tomohiro Ando Although risk factors for perioperative stroke during head and neck surgery are known, the risk of perioperative stroke in osteoradionecrosis (ORN) patients is scarcely known. Sixty-seven-year-old male presented ORN in the mandible after 9 years docetaxel, cisplatin, and 5-fluorouracil (TPF) chemo, and 66Gy radiation therapies for the oropharynx cancer, which was diagnosed Marx's classification class II. After pre-operative hyp...
Source: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology - January 1, 2015 Category: ENT & OMF Source Type: research